Inovio Pharmaceuticals (GBM) Stock Statistics & Valuation Metrics
Total Valuation
Inovio Pharmaceuticals has a market cap or net worth of EUR 149.42M. The enterprise value is EUR 61.11M.
- Market Cap
- EUR 149.42M
- Enterprise Value
- EUR 61.11M
Share Statistics
Inovio Pharmaceuticals has 103,397,514 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 103,397,514
- Owned by Insiders
- 0.38%
- Owned by Institutions
- 19.29%
Financial Efficiency
Inovio Pharmaceuticals’s return on equity (ROE) is -3.53 and return on invested capital (ROIC) is -259.45%.
- Return on Equity (ROE)
- -3.53
- Return on Assets (ROA)
- -1.14
- Return on Invested Capital (ROIC)
- -259.45%
- Return on Capital Employed (ROCE)
- -2.83
- Revenue Per Employee
- 583.42
- Profits Per Employee
- -758.45K
- Employee Count
- 112
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Inovio Pharmaceuticals is -1.24. Inovio Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -1.24
- PS Ratio
- 0.00
- PB Ratio
- 27.08
- Price to FCF
- -1.24
- Price to Operating Cash Flow
- -1.47
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of 65.34K and earned -84.95M in profits. Earnings per share was -1.81.
- Revenue
- 65.34K
- Gross Profit
- 65.34K
- Operating Income
- -86.82M
- Pretax Income
- -84.95M
- Net Income
- -84.95M
- EBITDA
- -81.96M
- Earnings Per Share (EPS)
- -1.81
Cash Flow
In the last 12 months, operating cash flow was -80.58M and capital expenditures -195,402, giving a free cash flow of -80.78M billion.
- Operating Cash Flow
- -80.58M
- Free Cash Flow
- -80.78M
- Free Cash Flow per Share
- -0.99
Dividends & Yields
Inovio Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -80.91%
- Earnings Yield
- -57.17%
Stock Price Statistics
- Beta
- 0.92
- 52-Week Price Change
- -31.85%
- 50-Day Moving Average
- 1.01
- 200-Day Moving Average
- 1.07
- Relative Strength Index (RSI)
- 67.22
- Average Volume (3m)
- 7,544
Important Dates
Inovio Pharmaceuticals upcoming earnings date is Nov 10, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Inovio Pharmaceuticals as a current ratio of 1.40, with Debt / Equity ratio of 38.88%
- Current Ratio
- 1.40
- Quick Ratio
- 1.40
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.43
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Inovio Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Inovio Pharmaceuticals EV to EBITDA ratio is -1.18, with an EV/FCF ratio of -0.94.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.18
- EV to Free Cash Flow
- -0.94
- EV to Operating Cash Flow
- -0.95
Balance Sheet
Inovio Pharmaceuticals has EUR 36.67M in cash and marketable securities with EUR 8.00M in debt, giving a net cash position of EUR 28.67M billion.
- Cash & Marketable Securities
- EUR 36.67M
- Total Debt
- EUR 8.00M
- Net Cash
- EUR 28.67M
- Net Cash Per Share
- EUR 0.28
- Tangible Book Value Per Share
- EUR 0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Inovio Pharmaceuticals is EUR 5.05, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 5.05
- Price Target Upside
- 243.41% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 57.95%
Scores
- Smart Score
- 8
- AI Score
- ―
